Literature DB >> 7198394

Influence of hypothermia or hyperthermia alone or in combination with pentobarbital or phenytoin on survival time in hypoxic mice.

A A Artru, J D Michenfelder.   

Abstract

The effect of temperature, either along or in combination with pentobarbital or phenytoin, on survival time in the hypoxic (Flo2 = 0.05) mouse was examined. With hypothermia alone only a mild level (35 C) was needed to increase survival time significantly (63%). Between 29 and 40 C, hypothermia alone increased hypoxic survival time and hyperthermia decreased it. When mild hypothermia was combined with moderate doses of pentobarbital or phenytoin, survival time was generally further increased, whereas at lower temperatures or increased drug doses the effect on survival time of combined treatments was unpredictable. In addition, the magnitude of the effect of hypothermia was quite different following injection of pentobarbital and following injection of phenytoin. The practical corollary of these results is that to obtain reproducible results with this model, the temperature of the mice should not vary more than +/- 0.2 to 0.3 C.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7198394

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  3 in total

1.  Postpartum stroke successfully treated with high-dose pentobarbitone therapy: a case report.

Authors:  N G Caseby
Journal:  Can Anaesth Soc J       Date:  1983-01

2.  Moderate hypoxia does not affect the zone of thermal comfort in humans.

Authors:  P Golja; A Kacin; M J Tipton; I B Mekjavic
Journal:  Eur J Appl Physiol       Date:  2005-01-22       Impact factor: 3.078

3.  Selection of orally active antifungal agents from 3,5-substituted isoxazolidine derivatives based on acute efficacy-safety profiles.

Authors:  G C Palmer; M J Ordy; R D Simmons; J C Strand; L A Radov; G B Mullen; C R Kinsolving; V St Georgiev; J T Mitchell; S D Allen
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.